Specific Drug Delivery to Cancer Cells with Double-Imprinted Nanoparticles against Epidermal Growth Factor Receptor

Area of Science:

• Biomaterials Science
• Nanotechnology
• Cancer Therapeutics

Background:

• Epidermal growth factor receptor (EGFR) is over-expressed in aggressive, drug-resistant triple-negative breast cancers.
• Conventional anti-EGFR antibodies face challenges including instability, high cost, and difficulty targeting membrane proteins.
• There is a need for alternative agents for specific cancer cell targeting and drug delivery.

Purpose of the Study:

• To design and develop supramolecular agents for targeted delivery to membrane proteins on cancer cells.
• To create molecularly imprinted polymer nanoparticles (nanoMIPs) loaded with doxorubicin for EGFR targeting.
• To establish a novel therapeutic approach as an alternative to traditional antibodies.

Main Methods:

• Utilized a novel double-imprinting approach on a solid-phase method to create nanoMIPs.
• Engineered nanoMIPs to target a specific linear epitope of EGFR on cancer cells.
• Loaded nanoMIPs with the chemotherapeutic agent doxorubicin.

Main Results:

• Doxorubicin-loaded anti-EGFR nanoMIPs demonstrated targeted delivery and binding to EGFR-overexpressing cells.
• The nanoMIPs successfully elicited cytotoxicity and apoptosis specifically in cancer cells with EGFR over-expression.
• The approach showed specificity, impacting only cells with the target membrane protein.

Conclusions:

• The developed nanoMIPs offer a viable alternative to conventional antibodies for targeting membrane proteins like EGFR.
• This technology presents a new paradigm for therapeutic applications of supramolecular agents in cancer treatment.
• NanoMIPs hold potential for developing advanced cell imaging tools against challenging targets such as membrane proteins.